Diabetes and acute coronary syndromes - A cardiologist's view

Diabetes and Vascular Disease Research

Volumn 2, Issue 3, 2005, Pages 101-102

  Marx, Nikolaus ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TIROFIBAN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; HEPARINIZATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 28144458560     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2005.024     Document Type: Editorial

References (4)

1. Otter W, Kleybrink S, Doering W, Standl E, Schnell O. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabet Med 2004;21:183-7.
2. Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
3. Cannon CP, Weintraub WS, Demopoulos EA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
4. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.